Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,otherCashflowsFromFinancingActivities,netBorrowings,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,CYTH,14321567,6358660,3258115,,-4036615,,-4036615,1097482,321871,-4037276,-4037276,,,,,,0,358133,4395409,36262,661,,-4036615,-4036615,52419383,3819702,14321567,18141269,635,-38098451,38942,15506718,3706760,60142,81222,18021105,220168,98382,257834,3628293,358560.0,3332.0,7584092.0,-1181842.0,7584092.0,2660605.0,-4926819.0,3550.0,-19925.0,-100847.0,50300.0,,,,14314345,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.23927428,7.55 - 7.6716,7.69,7.3,0.0,30,12,finmb_3103504,NasdaqCM,"Cyclo Therapeutics, Inc.",USD,202726,40166,4.6716,1.5572,3.0 - 21.0,-13.3284,-0.6346857,3.0,21.0,1607472000,-14400000,False,False,USD,REGULAR,-2.6,-2.9506154,8.122222,-0.45062208,-0.05548015,8.605,-0.9333997,-0.10847179,48781096,15,America/New_York,EDT,"Cyclo Therapeutics, Inc.",7.6716,1630503358,-0.018400192,7.41,7.6716,7.55,3701,0,NCM,2,us_market,-0.97,,,21.0,3.0,8.12,8.6,202.73k,40.17k,6.36M,,5.72M,13.31%,4.10%,112.83k,1.44,1.97%,1.77%,148.97k,,,,,,0.00%,"Dec 08, 2020",,1:100,"Dec 08, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,106.74%",-63.38%,-163.89%,935.77k,0.36,9.90%,829.79k,-10.34M,-10.34M,,,15.51M,2.44,191.41k,1.34,4.86,,-11.66M,-7.81M,Value,32653,Healthcare,8,"Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.",Gainesville,386 418 8060,FL,1609372800,United States,http://www.cyclotherapeutics.com,86400,6714 NW 16th Street,321 244 8351,Drug Manufacturers—Specialty & Generic,Suite B
t-1,CYTH,10452482,6358660,1236651,,-2679610,,-2679610,1568881,127479,-2681463,-2681463,,,,,,0,145586,2827049,18107,1853,,-2679610,-2679610,44513841,3735482,10452482,14187964,477,-34061836,49806,12846113,3672553,114029,87921,14050237,111789,44495,237909,3541041,-1169078.0,13211.0,13656625.0,334101.0,12671645.0,10608489.0,-3061347.0,3410.0,183415.0,14487.0,251928.0,984980.0,,,10377684,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.23927428,7.55 - 7.6716,7.69,7.3,0.0,30,12,finmb_3103504,NasdaqCM,"Cyclo Therapeutics, Inc.",USD,202726,40166,4.6716,1.5572,3.0 - 21.0,-13.3284,-0.6346857,3.0,21.0,1607472000,-14400000,False,False,USD,REGULAR,-2.6,-2.9506154,8.122222,-0.45062208,-0.05548015,8.605,-0.9333997,-0.10847179,48781096,15,America/New_York,EDT,"Cyclo Therapeutics, Inc.",7.6716,1630503358,-0.018400192,7.41,7.6716,7.55,3701,0,NCM,2,us_market,-0.97,,,21.0,3.0,8.12,8.6,202.73k,40.17k,6.36M,,5.72M,13.31%,4.10%,112.83k,1.44,1.97%,1.77%,148.97k,,,,,,0.00%,"Dec 08, 2020",,1:100,"Dec 08, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,106.74%",-63.38%,-163.89%,935.77k,0.36,9.90%,829.79k,-10.34M,-10.34M,,,15.51M,2.44,191.41k,1.34,4.86,,-11.66M,-7.81M,Value,32653,Healthcare,8,"Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.",Gainesville,386 418 8060,FL,1609372800,United States,http://www.cyclotherapeutics.com,86400,6714 NW 16th Street,321 244 8351,Drug Manufacturers—Specialty & Generic,Suite B
t-2,CYTH,-524533,6358660,1086753,,-1435609,,-1435609,555605,209476,-1435999,-1435999,,,,,,0,222462,1658461,12986,390,,-1435609,-1435609,30840706,4656969,-524533,4132436,16987,-31382226,64728,2237624,4559990,87421,95668,3972040,124565,71103,421324,4458191,473476.0,6536.0,2831115.0,-525700.0,2831115.0,1229269.0,-1608382.0,3117.0,-204715.0,75729.0,5320.0,984980.0,,,-587950,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.23927428,7.55 - 7.6716,7.69,7.3,0.0,30,12,finmb_3103504,NasdaqCM,"Cyclo Therapeutics, Inc.",USD,202726,40166,4.6716,1.5572,3.0 - 21.0,-13.3284,-0.6346857,3.0,21.0,1607472000,-14400000,False,False,USD,REGULAR,-2.6,-2.9506154,8.122222,-0.45062208,-0.05548015,8.605,-0.9333997,-0.10847179,48781096,15,America/New_York,EDT,"Cyclo Therapeutics, Inc.",7.6716,1630503358,-0.018400192,7.41,7.6716,7.55,3701,0,NCM,2,us_market,-0.97,,,21.0,3.0,8.12,8.6,202.73k,40.17k,6.36M,,5.72M,13.31%,4.10%,112.83k,1.44,1.97%,1.77%,148.97k,,,,,,0.00%,"Dec 08, 2020",,1:100,"Dec 08, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,106.74%",-63.38%,-163.89%,935.77k,0.36,9.90%,829.79k,-10.34M,-10.34M,,,15.51M,2.44,191.41k,1.34,4.86,,-11.66M,-7.81M,Value,32653,Healthcare,8,"Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.",Gainesville,386 418 8060,FL,1609372800,United States,http://www.cyclotherapeutics.com,86400,6714 NW 16th Street,321 244 8351,Drug Manufacturers—Specialty & Generic,Suite B
t-3,CYTH,-1920039,6358660,1713435,,-2192392,,-2192392,679414,195336,-2201903,-2201903,,,,,,0,209594,2411497,14258,9511,,-2192392,-2192392,28012423,4182340,-1920039,2262301,14155,-29946617,71264,1008355,4057242,60879,102952,2088085,200294,97645,216609,3979395,36970.0,7217.0,2128887.0,74121.0,1970363.0,74898.0,-2061206.0,3118.0,12162.0,7590.0,-2775.0,984980.0,158524.0,-2500.0,-1969157,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.23927428,7.55 - 7.6716,7.69,7.3,0.0,30,12,finmb_3103504,NasdaqCM,"Cyclo Therapeutics, Inc.",USD,202726,40166,4.6716,1.5572,3.0 - 21.0,-13.3284,-0.6346857,3.0,21.0,1607472000,-14400000,False,False,USD,REGULAR,-2.6,-2.9506154,8.122222,-0.45062208,-0.05548015,8.605,-0.9333997,-0.10847179,48781096,15,America/New_York,EDT,"Cyclo Therapeutics, Inc.",7.6716,1630503358,-0.018400192,7.41,7.6716,7.55,3701,0,NCM,2,us_market,-0.97,,,21.0,3.0,8.12,8.6,202.73k,40.17k,6.36M,,5.72M,13.31%,4.10%,112.83k,1.44,1.97%,1.77%,148.97k,,,,,,0.00%,"Dec 08, 2020",,1:100,"Dec 08, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,106.74%",-63.38%,-163.89%,935.77k,0.36,9.90%,829.79k,-10.34M,-10.34M,,,15.51M,2.44,191.41k,1.34,4.86,,-11.66M,-7.81M,Value,32653,Healthcare,8,"Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.",Gainesville,386 418 8060,FL,1609372800,United States,http://www.cyclotherapeutics.com,86400,6714 NW 16th Street,321 244 8351,Drug Manufacturers—Specialty & Generic,Suite B
